LRRK2 and Parkinson disease: In addition, it has been noted that PD patients who carried a G2019S LRRK2 mutation had higher GCase activity than non-carriers with concomitant elevation in levels of the lysosomal enzymes acid sphingomyelinase and alpha galactosidase A [65, 66].